Back to Search
Start Over
Andrographis paniculata extract versus placebo in the treatment of COVID-19: a double-blinded randomized control trial
- Source :
- Research in Pharmaceutical Sciences, Vol 18, Iss 6, Pp 592-603 (2023)
- Publication Year :
- 2023
- Publisher :
- Wolters Kluwer Medknow Publications, 2023.
-
Abstract
- Background and purpose: Andrographis paniculata (Burm.f.) Nees has been recommended to relieve symptoms and decrease the severity of COVID-19. The clinical study aimed to investigate the efficacy and safety of A. paniculata ethanolic extract (APE). Experimental approach: The efficacy and safety of APE in asymptomatic or mildly symptomatic COVID-19 patients compared with placebo were investigated through a prospective, double-blind randomized control trial. Patients received APE containing 60 mg of andrographolide, three times a day for five days. WHO progression scale, COVID-19 symptoms, and global assessment evaluated the efficacy and adverse events, liver and renal functions were monitored for safety. Findings/Results: 165 patients completed the study (83 patients in the APE group and 82 patients in the placebo group). The highest WHO progression scale was 4 and COVID-19 symptoms were significantly relieved on the last day of intervention in both groups, with no significant difference between groups. APE significantly relieved headache symptoms on day 1 and olfactory loss symptoms on day 2 compared to placebo. The global assessment showed that 80.7% of patients had total recovery after 5-day treatment with APE. Mild diarrhea was the most common side effect with a high dose that resolved within a few days. No hepatic or renal toxicity was associated with treatment. Conclusion and implications: APE at 180 mg/day for 5 days did not reduce COVID-19 progression in asymptomatic or mildly afflicted COVID-19 patients, however, it shortened the symptoms of olfactory loss with no adverse effects over 5 days of use.
- Subjects :
- capsule
clinical trial
coronavirus
hplc.
Pharmacy and materia medica
RS1-441
Subjects
Details
- Language :
- English
- ISSN :
- 17355362 and 17359414
- Volume :
- 18
- Issue :
- 6
- Database :
- Directory of Open Access Journals
- Journal :
- Research in Pharmaceutical Sciences
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.bbc8adedd9b84a5a993c07546e5ae860
- Document Type :
- article
- Full Text :
- https://doi.org/10.4103/1735-5362.389947